Meticulous Research®—a leading global market research company, published a research report titled ‘Recombinant Coagulation Factors Market by Type (Factor VIII, Factor IX) Source (CHO, HEK) Application (Hemophilia A, Hemophilia B, Von Willebrand Disease) End User (Hospitals & Clinics, Clinical Research Laboratories) Geography - Global Forecast to 2030.’

Download Sample @ https://www.meticulousresearch.com/download-sample-report/cp_id=1254?utm_source=Article&utm_medium=Social&utm_campaign=Product

According to this latest publication from Meticulous Research®, the recombinant coagulation factors market is projected to reach $24.21 billion by 2030, at a CAGR of 8.6% during the forecast period. The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors, and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market. Furthermore, the potential emerging economies and rising healthcare expenditure are expected to offer significant growth opportunities for the recombinant coagulation factors market.
However, the high cost of recombinant factors compared to plasma-derived ones and the limited accessibility and availability of recombinant clotting factors in developing & underdeveloped countries are expected to restrain the growth of this market. Additionally, manufacturing challenges in the production of recombinant coagulation factors, stringent regulatory requirements, lack of reimbursement in some countries, and lack of awareness among patients are some of the challenges to the growth of this market.

Request Sample@ https://www.meticulousresearch.com/request-sample-report/cp_id=1254?utm_source=Article&utm_medium=Social&utm_campaign=Product

Recombinant Coagulation Factors Market: Future Outlook
The recombinant coagulation factors market is segmented based on Type (Recombinant Factors VIII, Recombinant Factor IX, and Other Types), Source (Chinese Hamster Ovary (CHO) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Other Sources), Application (Hemophilia A, Hemophilia B, and Other Applications), End User (Hospitals & Clinics and Clinical Research Laboratories), and Geography. The study also evaluates industry competitors and analyzes the market at the regional and country levels.
Based on type, in 2023, the recombinant factor VIII segment is expected to account for the largest share of the recombinant coagulation factors market. This segment's large market share is attributed to the rising prevalence of bleeding disorders, the high efficacy of recombinant factor VIII, and the higher adoption compared to other types due to the well-established presence of recombinant factor VIII in the market since 1992.
Based on source, the recombinant coagulation factors market is segmented into Chinese hamster ovary (CHO) cell line, human embryonic kidney (HEK) cell line, and other sources. In 2023, the Chinese hamster ovary (CHO) cell line segment is expected to account for the largest share of the recombinant coagulation factors market. The large market share of this segment is attributed to the higher utilization of CHO cell lines and their advantages, such as the ability to generate glycosylation profiles of humankind, high reproducibility, and easy manipulation.

Product @ https://www.meticulousresearch.com/product/recombinant-coagulation-factors-market-1254?utm_source=Article&utm_medium=Social&utm_campaign=Product

Based on application, the recombinant coagulation factors market is segmented into hemophilia A, hemophilia B, and other applications. In 2023, the hemophilia A segment is expected to account for the largest share of this market. The large share of this segment is attributed to the high prevalence of hemophilia A, the rising adoption of recombinant coagulation factors for the treatment of hemophilia A, and increased patient awareness about the disease.
Based on end user, the recombinant coagulation factors market is segmented into hospitals & clinics, and clinical research laboratories. In 2023, the hospitals & clinics segment is expected to account for the largest share of this market. The large market share of this segment is attributed to the high utilization of recombinant coagulation factors in hospitals & clinics and increased awareness among healthcare professionals regarding advanced treatment options.

Quick Buy @ https://www.meticulousresearch.com/Checkout/95626007?utm_source=Article&utm_medium=Social&utm_campaign=Product

This research report analyzes major geographies and provides comprehensive market insights into North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Netherlands, Sweden, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.

Geographic Review

In 2023, North America is expected to account for the largest share of the recombinant coagulation factors market, followed by Europe and Asia-Pacific. Furthermore, in 2023, the U.S. is expected to account for the largest share of the North America market. The large share of his market is attributed to the robust healthcare infrastructure, high patient awareness about recombinant coagulation factors for the treatment of coagulation disorders, high R&D expenditure, and high favorable reimbursement scenarios.

Download Sample @ https://www.meticulousresearch.com/Checkout/95626007?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=18-04-2024